Bioengineered human heart developer Biolife4D files for $17M IPO
seekingalpha.com
economics
2022-06-03 23:10:52

Mikko Lemola/iStock via Getty Images Biolife4D (SAVU), which is developing bioengineered human hearts for research and possible transplantation, has filed to hold a $17.3M initial public offering. The biotech company's filing didn't disclose the number and pricing of the shares to be offered, but said that the deal would likely include warrants and pre-funded warrants. A filing fee schedule indicated it was seeking to raise up to $17.3M. Biolife4D has applied to list its shares on Nasdaq under the symbol SAVU.
